NCT07248228 Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)
| NCT ID | NCT07248228 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Case Comprehensive Cancer Center |
| Condition | Brain Metastases |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2026-07-09 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 90 participants in total. It began in 2026-07-09 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve cognitive function. This study compares that approach to another approach of whole brain radiotherapy that stays away from additional structures that are thought to have a role in cognitive function. Researchers want to see if there is a difference in the preservation of cognitive function between these two approaches.
Eligibility Criteria
Inclusion Criteria: * Participants must have histologically, cytologically, or radiographically confirmed diagnosis of solid tumor with brain metastases * Age \>18 years * Performance status: Karnofsky Performance Status (KPS) ≥ 70 * Estimated life expectancy of at least 3 months * Participant must be considered a candidate for WBRT by the treating physician * Participant must be a primary English speaker and have the ability to understand and the willingness to sign an English written informed consent document * Participant has at least 10 brain metastases or is otherwise suitable for WBRT Exclusion Criteria: * Prior whole brain radiation * Participant has Multiple Sclerosis, Alzheimer's, dementia, or mental disability * Pregnant or breastfeeding women are excluded from this study. * Participant is not able to receive an MRI * Participant has metastasis within avoidance neurocognitive substructures (hippocampus, amygdala, fornix, corpus callosum, pituitary, amygdala)
Contact & Investigator
Haley Perlow, MD
PRINCIPAL INVESTIGATOR
Case Comprehensive Cancer Center, University Hospitals
Frequently Asked Questions
Who can join the NCT07248228 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07248228 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT07248228 currently recruiting?
Yes, NCT07248228 is actively recruiting participants. Contact the research team at haley.perlow@uhhospitals.org for enrollment information.
Where is the NCT07248228 trial being conducted?
This trial is being conducted at Cleveland, United States.
Who is sponsoring the NCT07248228 clinical trial?
NCT07248228 is sponsored by Case Comprehensive Cancer Center. The principal investigator is Haley Perlow, MD at Case Comprehensive Cancer Center, University Hospitals. The trial plans to enroll 90 participants.